Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yongping Song

Showing results (61-70 of 252) with videos related to

Pageof 26
Sort By:
Journal of Translational Medicine|December 12, 2022
Targeting macrophages: a novel treatment strategy in solid tumorsMengmeng Liu, Lina Liu, Yongping Song, et al.
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion|August 8, 2019
Clinical Efficacy and Safety of High-Dose Dexamethasone Plus Low-Dose Rituximab as First-Line Therapy in Newly Diagnosed Primary Immune ThrombocytopeniaHu Zhou, Liu Liu, Xinhui Shu, et al.
Experimental Hematology & Oncology|January 25, 2022
Research progress on dendritic cell vaccines in cancer immunotherapyJifeng Yu, Hao Sun, Weijie Cao, et al.
Genes & Diseases|July 1, 2024
Exploiting the potential of the ubiquitin-proteasome system in overcoming tyrosine kinase inhibitor resistance in chronic myeloid leukemiaXudong Li, Wei Li, Yanli Zhang, et al.
Experimental Hematology & Oncology|February 27, 2024
Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meetingJingyi Yang, Hao Guo, Lu Han, et al.
Journal of Hematology & Oncology|August 3, 2023
Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual MeetingJuanjuan Zhao, Quan Ren, Xinyuan Liu, et al.
Journal of Hematology & Oncology|July 25, 2016
EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancerShuhang Wang, Stella T Tsui, Christina Liu, et al.
Case Reports in Oncology|April 26, 2011
Imatinib plus Granulocyte Colony-Stimulating Factor in Chronic Myeloid Leukemia Patients Who Have Achieved Partial or Complete Cytogenetic Response while on ImatinibBaijun Fang, Ling Mai, Ning Li, et al.
Annals of Hematology|May 26, 2010
Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with imatinibBaijun Fang, Ning Li, Yongping Song, et al.
Biotechnology Letters|March 24, 2009
Comparison of human post-embryonic, multipotent stem cells derived from various tissuesBaijun Fang, Ning Li, Yongping Song, et al.
Pageof 26

Showing results (61-70 of 252) with videos related to

Sort By:
Pageof 26
Journal of Translational Medicine|December 12, 2022
Targeting macrophages: a novel treatment strategy in solid tumorsMengmeng Liu, Lina Liu, Yongping Song, et al.
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion|August 8, 2019
Clinical Efficacy and Safety of High-Dose Dexamethasone Plus Low-Dose Rituximab as First-Line Therapy in Newly Diagnosed Primary Immune ThrombocytopeniaHu Zhou, Liu Liu, Xinhui Shu, et al.
Experimental Hematology & Oncology|January 25, 2022
Research progress on dendritic cell vaccines in cancer immunotherapyJifeng Yu, Hao Sun, Weijie Cao, et al.
Genes & Diseases|July 1, 2024
Exploiting the potential of the ubiquitin-proteasome system in overcoming tyrosine kinase inhibitor resistance in chronic myeloid leukemiaXudong Li, Wei Li, Yanli Zhang, et al.
Experimental Hematology & Oncology|February 27, 2024
Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meetingJingyi Yang, Hao Guo, Lu Han, et al.
Journal of Hematology & Oncology|August 3, 2023
Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual MeetingJuanjuan Zhao, Quan Ren, Xinyuan Liu, et al.
Journal of Hematology & Oncology|July 25, 2016
EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancerShuhang Wang, Stella T Tsui, Christina Liu, et al.
Case Reports in Oncology|April 26, 2011
Imatinib plus Granulocyte Colony-Stimulating Factor in Chronic Myeloid Leukemia Patients Who Have Achieved Partial or Complete Cytogenetic Response while on ImatinibBaijun Fang, Ling Mai, Ning Li, et al.
Annals of Hematology|May 26, 2010
Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with imatinibBaijun Fang, Ning Li, Yongping Song, et al.
Biotechnology Letters|March 24, 2009
Comparison of human post-embryonic, multipotent stem cells derived from various tissuesBaijun Fang, Ning Li, Yongping Song, et al.
Pageof 26